BIOMAT Database Logo BIOMAT Database Logo

M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced carcinoma of the bladder. The French Federation of Cancer Centers experience. 1991

A Boutan-Laroze, and M Mahjoubi, and J P Droz, and P Charrot, and P Fargeot, and P Kerbrat, and A Caty, and P M Voisin, and M Spielmann, and A Rey
Department of Medicine, Institut Gustave-Roussy, Villejuif, France.

70 patients with advanced transitional cell carcinoma of the bladder received methotrexate, vinblastine, doxorubicin and cisplatin (M-VAC). Complete responses (CR) were obtained in 13 of the 67 (19%) evaluable patients and partial responses (PR) in 25 patients for an objective response rate of 57% (95% CI 45-69%). Of the 54 patients who have had a minimum follow-up of 2 years, 8 patients (15%) are disease-free or have stable residual disease. Median survival of the 70 patients was 13 months. Toxicity was acceptable with no drug-related deaths. Because of myelosuppression, only 15 patients (21%) received treatment without delays in drug administration or modifications from the planned schedule. Our results confirm that this regimen is effective, with some patients being long-term survivors.

UI MeSH Term Description Entries
D008297 Male Males
D008727 Methotrexate An antineoplastic antimetabolite with immunosuppressant properties. It is an inhibitor of TETRAHYDROFOLATE DEHYDROGENASE and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of DNA. Amethopterin,Methotrexate Hydrate,Methotrexate Sodium,Methotrexate, (D)-Isomer,Methotrexate, (DL)-Isomer,Methotrexate, Dicesium Salt,Methotrexate, Disodium Salt,Methotrexate, Sodium Salt,Mexate,Dicesium Salt Methotrexate,Hydrate, Methotrexate,Sodium, Methotrexate
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D001749 Urinary Bladder Neoplasms Tumors or cancer of the URINARY BLADDER. Bladder Cancer,Bladder Neoplasms,Cancer of Bladder,Bladder Tumors,Cancer of the Bladder,Malignant Tumor of Urinary Bladder,Neoplasms, Bladder,Urinary Bladder Cancer,Bladder Cancers,Bladder Neoplasm,Bladder Tumor,Cancer, Bladder,Cancer, Urinary Bladder,Neoplasm, Bladder,Neoplasm, Urinary Bladder,Tumor, Bladder,Tumors, Bladder,Urinary Bladder Neoplasm
D002295 Carcinoma, Transitional Cell A malignant neoplasm derived from TRANSITIONAL EPITHELIAL CELLS, occurring chiefly in the URINARY BLADDER; URETERS; or RENAL PELVIS. Carcinomas, Transitional Cell,Cell Carcinoma, Transitional,Cell Carcinomas, Transitional,Transitional Cell Carcinoma,Transitional Cell Carcinomas
D002945 Cisplatin An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle. Platinum Diamminodichloride,cis-Diamminedichloroplatinum(II),cis-Dichlorodiammineplatinum(II),Biocisplatinum,Dichlorodiammineplatinum,NSC-119875,Platidiam,Platino,Platinol,cis-Diamminedichloroplatinum,cis-Platinum,Diamminodichloride, Platinum,cis Diamminedichloroplatinum,cis Platinum
D004317 Doxorubicin Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN. Adriamycin,Adriablastin,Adriablastine,Adriblastin,Adriblastina,Adriblastine,Adrimedac,DOXO-cell,Doxolem,Doxorubicin Hexal,Doxorubicin Hydrochloride,Doxorubicin NC,Doxorubicina Ferrer Farm,Doxorubicina Funk,Doxorubicina Tedec,Doxorubicine Baxter,Doxotec,Farmiblastina,Myocet,Onkodox,Ribodoxo,Rubex,Urokit Doxo-cell,DOXO cell,Hydrochloride, Doxorubicin,Urokit Doxo cell
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

A Boutan-Laroze, and M Mahjoubi, and J P Droz, and P Charrot, and P Fargeot, and P Kerbrat, and A Caty, and P M Voisin, and M Spielmann, and A Rey
M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium.
March 1988, The Journal of urology,
A Boutan-Laroze, and M Mahjoubi, and J P Droz, and P Charrot, and P Fargeot, and P Kerbrat, and A Caty, and P M Voisin, and M Spielmann, and A Rey
Neoadjuvant M-VAC (methotrexate, vinblastine, doxorubicin, and cisplatin) for infiltrating transitional cell carcinoma of the bladder.
September 1993, Cancer,
A Boutan-Laroze, and M Mahjoubi, and J P Droz, and P Charrot, and P Fargeot, and P Kerbrat, and A Caty, and P M Voisin, and M Spielmann, and A Rey
M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) chemotherapy for transitional cell carcinoma: the Princess Margaret Hospital experience.
August 1989, The Journal of urology,
A Boutan-Laroze, and M Mahjoubi, and J P Droz, and P Charrot, and P Fargeot, and P Kerbrat, and A Caty, and P M Voisin, and M Spielmann, and A Rey
Neoadjuvant M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) effect on the primary bladder lesion.
March 1988, The Journal of urology,
A Boutan-Laroze, and M Mahjoubi, and J P Droz, and P Charrot, and P Fargeot, and P Kerbrat, and A Caty, and P M Voisin, and M Spielmann, and A Rey
Phase II evaluation of methotrexate, vinblastine, doxorubicin, and cisplatin (M-VAC) in advanced, measurable breast carcinoma.
January 1995, Cancer investigation,
A Boutan-Laroze, and M Mahjoubi, and J P Droz, and P Charrot, and P Fargeot, and P Kerbrat, and A Caty, and P M Voisin, and M Spielmann, and A Rey
Advanced bladder cancer: the need to identify new agents in the post-M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) world.
March 1995, The Journal of urology,
A Boutan-Laroze, and M Mahjoubi, and J P Droz, and P Charrot, and P Fargeot, and P Kerbrat, and A Caty, and P M Voisin, and M Spielmann, and A Rey
M-VAC (methotrexate, vinblastine, adriamycin and cisplatin) and bladder preservation.
January 1990, Progress in clinical and biological research,
A Boutan-Laroze, and M Mahjoubi, and J P Droz, and P Charrot, and P Fargeot, and P Kerbrat, and A Caty, and P M Voisin, and M Spielmann, and A Rey
[Combination chemotherapy of M-VAC (methotrexate, vinblastine, adriamycin and cisplatin) for advanced uroepithelial cancer].
March 1990, Nihon Hinyokika Gakkai zasshi. The japanese journal of urology,
A Boutan-Laroze, and M Mahjoubi, and J P Droz, and P Charrot, and P Fargeot, and P Kerbrat, and A Caty, and P M Voisin, and M Spielmann, and A Rey
Methotrexate, vinblastine, adriamycin and cisplatin (M-VAC) for advanced TCC of urothelium.
July 1992, Journal of the Formosan Medical Association = Taiwan yi zhi,
A Boutan-Laroze, and M Mahjoubi, and J P Droz, and P Charrot, and P Fargeot, and P Kerbrat, and A Caty, and P M Voisin, and M Spielmann, and A Rey
Neoadjuvant M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for extravesical urinary tract tumors.
March 1988, The Journal of urology,
Copied contents to your clipboard!